Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial

Ahmet Sezer, Saadettin Kılıçkap, Mahmut Gümüş, Igor Bondarenko, Mustafa Özgüroğlu, Miranda Gogishvili, Hacı Mehmet Türk, İrfan Çiçin, Dmitry Bentsion, Oleg Gladkov, Philip R. Clingan, Virote Sriuranpong, Naiyer A. Rizvi, Bo Gao, Siyu Li, Sue Lee, Kristina McGuire, Chieh-I Chen, Tamta Makharadze, Semra Paydaş, Marina Nechaeva, Frank Seebach, David M. Weinreich, George D. Yancopoulos, Giuseppe Gullo, Israel Lowy, Petra Rietschel